Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. (NCT06059261) | Clinical Trial Compass
RecruitingPhase 2
Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
China30 participantsStarted 2026-02-09
Plain-language summary
This is a single-center, prospective, single-arm, phase II clinical study, to evaluate the therapeutic efficacy and safety of envafolimab combined with chemoradiotherapy and recombinant human endostatin in patients with locally advanced nasopharyngeal carcinoma.
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. ECOG score 0-1.
✓. Aged 18-65 years, male or non-pregnant female;
✓. Pathologically confirmed diagnosis of nasopharyngeal non-keratinizing carcinoma (differentiated or undifferentiated, WHO type II or III) without the need to detect MSI and dMMR status.
✓. high-risk locally advanced stage III-IVA (8th AJCC/UICC staging), i.e., T4N+ or N2-3, or pretreatment EBV-DNA ≥4000 copies/ml, or lymph node extra-envelope invasion grade 3 (invasion of muscle skin, etc.), treatment-naive nasopharyngeal carcinoma patients.
✓. MRI data of nasopharynx and neck before enrollment, and measurable lesions;
✓. Agree to provide a previously stored tumor tissue specimen or biopsy to collect tumor lesion tissue and send it to the central laboratory for PD-L1 IHC testing.
✓. Agree to undergo EBV antibody and EBV-DNA quantitative testing before receiving treatment.
. Pregnant or lactating women, in the reproductive period without effective contraceptive measures;
✕. HIV positive.
✕. Having had other malignancies (except cured basal cell carcinoma or cervical carcinoma in situ);
✕. Patients who have been treated with inhibitors of immune regulatory points (CTLA-4, PD-1, PD-L1, etc.);
✕. Patients need long-term use of immunosuppressive drug therapy, or systemic or local use of immunosuppressive doses of corticosteroids complications;